Free Newsletter
Researchers explore brain cancer vaccine
Researchers are touting the early results from a study of a new brain cancer vaccine that combines protein antigens extracted from a patient's tumor and matches them with white cells also drawn from the patient. The therapy is injected into patients, spurring T-cells to attack the remaining cancer cells after tumor-removal surgery. The vaccine, DCVax-Brain, is being developed by Bothell, WA-based Northwest Biotherapeutics.
"I've never seen a clinical trial that's had this promise," said Dr. Michael Gruber, medical director of the Brain Tumor Center of New Jersey.
- read the article from the Monterey Herald
Comments
Post new comment
Paid Research Reports
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
- Innovative Drug Discovery in Emerging Markets
- Market Opportunities for Supergenerics
- The Future of In Vitro and In Vivo Diagnostic Integration
More Research Reports >>
SHARE
WITH: